Kinnari Patel - Feb 21, 2025 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Role
President, Head of R&D and Chief Operating Officer
Signature
/s/ Martin Wilson, as attorney-in-fact for Kinnari Patel
Stock symbol
RCKT
Transactions as of
Feb 21, 2025
Transactions value $
-$64,305
Form type
4
Date filed
2/25/2025, 04:01 PM
Previous filing
Feb 13, 2025
Next filing
Apr 10, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCKT Common Stock Sale -$64.3K -6.08K -1.35% $10.58 444K Feb 21, 2025 Direct F1, F2
holding RCKT Common Stock 5.68K Feb 21, 2025 By Spouse
holding RCKT Common Stock 105K Feb 21, 2025 By Adaptive Technology LLC F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
F2 The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.
F3 The shares are held indirectly through Adaptive Technology, LLC, a limited liability company that is owned and managed by the reporting person's husband.

Remarks:

President, Head of R&D and Chief Operating Officer